Intranasal Carbetocin Reduces Hyperphagia, Anxiousness and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial. Elizabeth Roof , Cheri L Deal , Shawn E McCandless , Ronald L Cowan , Jennifer L Miller , Jill K Hamilton , Elizabeth R Roeder , Shana E McCormack , Tamanna R Roshan Lal , Hussein D Abdul-Latif , Andrea M Haqq , Kathryn S Obrynba , Laura C Torchen , Alaina P Vidmar , David H Viskochil , Jean-Pierre Chanoine , Carol K L Lam , Melinda J Pierce , Laurel L Williams , Lynne M Bird , Merlin G Butler , Diane E Jensen , Susan E Myers , Oliver J Oatman , Charumathi Baskaran , Laura J Chalmers , Cary Fu , Nathalie Alos , Scott D McLean , Ajay Shah , Barbara Y Whitman , Brent A Blumenstein , Sarah F Leonard , Jessica P Ernest , Joseph W Cormier , Sara P Cotter , Davis C Ryman The Journal of clinical endocrinology and metabolism（2023）
摘要
Carbetocin was well tolerated, and the 3.2 mg dose was associated with clinically meaningful improvements in hyperphagia and anxiousness and distress behaviors in participants with PWS.
更多 查看译文
关键词
Prader-Willi syndrome, anxiety, carbetocin, hyperphagia, oxytocin, vasopressin
AI 理解论文
溯源树
样例
